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  17 
Synopsis    18 
Background: The better use of new and emerging data streams to understand the 19 
epidemiology of infectious disease and to inform and evaluate antimicrobial 20 
stewardship improvement programmes is paramount in the global fight against 21 
antimicrobial resistance.   22 
Objectives: To create a national informatics platform that synergises the wealth of 23 
disjointed, infection-related health data, building intelligence capability that allows 24 
rapid enquiry, generation of new knowledge and feedback to clinicians and policy 25 
makers.  26 
Methods:  A multi-stakeholder community, led by the Scottish Antimicrobial 27 
Prescribing Group, secured government funding to deliver a national program of work 28 
centred on three key aspects: technical platform development with record linkage 29 
capability across multiple datasets; a proportionate governance approach to enhance 30 
responsiveness; generation of new evidence to guide clinical practice. 31 
Results:  The National Health Service Scotland Infection Intelligence Platform (IIP) is 32 
now hosted within the national health data repository to assure resilience and 33 
sustainability.  New technical solutions include VLPSOLILHG ³GDWD YLHZV´ RI FRPSOH[, 34 
linked datasets and embedded statistical programmes to enhance capability.  These 35 
developments have enabled responsiveness, flexibility and robustness in conducting 36 
population-based studies including a focus on intended and unintended effects of 37 
antimicrobial stewardship interventions and quantification of infection risk factors and 38 
clinical outcomes. 39 
Conclusion:  We have completed the build and test phase of IIP, overcoming the 40 
technical and governance challenges and produced new capability in infection 41 
informatics, generating new evidence for improved clinical practice. This provides a 42 
foundation for expansion and opportunity for global collaborations. 43 
 44 
 45 
  46 
Introduction  47 
Health systems are generating increasing volumes of routine clinical data as 48 
individuals interact with healthcare services. Strategies for surveillance of 49 
Antimicrobial resistance (AMR) and to address emergent problems, requires intelligent 50 
use of these new and emerging data streams to augment understanding of the 51 
epidemiology of infectious disease nationally, and contribute to the global public health 52 
effort against the threat of AMR.1-3    53 
In the UK, the AMR Strategy (2013-2018) defined as a key action, better access to 54 
and use of surveillance data, and recognised that current information on the impact of 55 
antimicrobial use on patient outcome and development of resistance was limited.4 In 56 
response the Scottish Antimicrobial Management of Resistance Action Plan called for 57 
development of a National Health Service (NHS) Scotland Infection Intelligence 58 
Platform (IIP) recognising the importance of informatics to empower clinicians and 59 
healthcare systems to measure the intended and unintended consequences of 60 
interventions to prevent and treat infections.5 The IIP is an ambitious programme that 61 
aims to move to a position of enhanced connectivity of datasets to achieve a 62 
comprehensive, dynamic and responsive integrated informatics resource to support 63 
improvements in outcomes for patients with, or at risk of, infection.6  Underpinning this 64 
was our aim to create a more collegiate community of infection control and 65 
stewardship clinicians, supported by IIP, to deliver better informed clinical decisions, 66 
guide national policy and contribute to the global AMR effort.  In this paper we describe 67 
our early experiences and results in developing the IIP.  68 
  69 
Methods  70 
The AMR policy frameworks provided the stimulus and environment to build a broad 71 
coalition of clinicians and national stakeholders to co-create the vision for IIP ± to 72 
improve patient outcomes and reduce harm from infection through innovative data 73 
integration to support clinicians within the NHS in Scotland. Led by the Scottish 74 
Antimicrobial Prescribing Group (SAPG) and supported by NHS National Services 75 
Scotland (NSS), stakeholders from policy, clinical practice and academia produced a 76 
proposal describing the benefits of, and target deliverables from, the creation of a 77 
national infection informatics resource. Initial funding was secured from Scottish 78 
Government for the initial IIP program from 2013 to 2017.  The programme focused 79 
on three areas:   80 
x Technical platform development to enable linking of varied NHS datasets to 81 
enhance surveillance capability, analysis and responsiveness 82 
x Implementation of proportionate information governance best practices to enable 83 
efficient, agile response to important clinical questions  84 
x Generation of new evidence for improved clinical practice through clinical exemplar 85 
studies using the IIP    86 
Record linkage capability was core to the IIP development.  In NHS Scotland all 87 
individuals have a unique patient identifier - the Community Health Index (CHI) number 88 
± which enables records for the same patient to be linked across multiple health 89 
UHFRUGVGDWDFDSWXULQJDSDWLHQW¶VSDWKZD\WKURXJKWKHKHDOWKFDUHV\VWHP.7 NHS NSS 90 
hosts a range of national health datasets which was the initial focus for IIP.  On review, 91 
these datasets contained a wealth of information applicable to infection but these were 92 
poorly connected and underused by the diverse clinical communities who could benefit 93 
from better integration. Supported by a clinical user community prioritisation exercise 94 
eight datasets were initially selected for inclusion within the IIP (table1).  95 
Data access is controlled through NSS Information Governance Procedures ensuring 96 
NSS analysts can only access IIP data views for which they have underlying dataset 97 
approval.  In addition, generic ethics and privacy approval for the conduct of linkage 98 
studies under the programme was secured with documentation of analyses for audit 99 
purposes.   100 
  101 
Results 102 
The IIP is hosted within the NSS Corporate Data Warehouse (CDW), the central 103 
repository for national datasets, connected by a standardised set of common 104 
dimensions. ,,3 WHFKQLFDO GHYHORSPHQWV HQDEOHG WKH FUHDWLRQ RI YLUWXDO ³VLPSOLILHG105 
YLHZV´ RI HDFK ,,3 Gataset e.g. the SMR01 view joins over 36 tables in a flat-like 106 
structure to expose 50 variables which meet the majority of infection analysis 107 
requirements. Analysts run queries across these views within the IIP statistical 108 
platform. Further functionality includes a cohort solution enabling definition and 109 
extraction of patient cohorts from across datasets, storable for repeated use.8  110 
The main benefits arising from the IIP technical build have been: improved data 111 
security and reduced errors with fewer data extracts (reducing human errors in multiple 112 
file extraction and subsequent linkage) as statistical packages process data directly in 113 
the CDW; better flexibility in running repeated linkages and refreshing reporting for 114 
common queries; and capability to retain and share analysis programing scripts, 115 
backed up within the IIP.   116 
The key deliverable beyond creating the platform and assuring robust governance was 117 
the completion of data linkage studies, pertinent to the clinical community, to test the 118 
agility and robustness of the IIP to inform national policy and antimicrobial prescribing 119 
practice.  This has been delivered through a series of studies under two broad themes: 120 
intended and unintended effects of antimicrobial stewardship and infection 121 
management intervention; and infection risk factors and clinical outcomes, Table 2 122 
summarises key studies which provide: reassurance to the clinical community as we 123 
seek to safely reduce antimicrobial use; national quantification of clinical outcomes 124 
following a healthcare associated infection (HAI), and; application of data at scale to 125 
identify and quantify risks associated with infection to inform development of patient 126 
centred clinical decision tools.   This evidence is shared with the clinical community 127 
through SAPG, the IIP website, regular newsletters and publication/presentation at 128 
international meetings (Table 2).6 129 
  130 
Platform development and evidence generation has been underpinned by two 131 
components: a skills development programme for analytical and statistical staff 132 
supported through a joint academic-NHS network to build capability and capacity in 133 
infection informatics, and a clinical engagement and communication strategy to build 134 
awareness and knowledge of the IIP potential in supporting infection management and 135 
control.     136 
 137 
Discussion  138 
In Scotland taking a national perspective to infection informatics was logical given: the 139 
population size (approximately 5.3 million); a national, clinically led approach to 140 
antimicrobial stewardship and infection control, and our capability to capture 141 
comprehensive healthcare activity for all citizens. IIP sought to build on earlier Scottish 142 
experiences gained in diabetes through the Scottish Care Information ± Diabetes 143 
Collaboration [SCI-DC],9 a national collaboration which has successfully supported 144 
this community in providing and improving patient care, screening services and data 145 
for improvement.10  146 
Previously, Scottish infection publications mainly involved small scale studies11,12 147 
working with local NHS Health Board datasets but the infection community wished to 148 
maximise use of existing data to replicate such studies nationally. This desire, coupled 149 
with the evolving national and international health policy frameworks, recognising the 150 
role of health informatics, provided the environment to articulate the benefits of 151 
investing in a national IIP which has enabled:  152 
x Better identification of the intrinsic and extrinsic risk factors for, and outcomes from,  153 
infection  154 
x Better clinical decision making through enhanced intelligence on best practice 155 
x More rapid, effective identification of unintended consequences of antimicrobial 156 
misuse 157 
x Improved measurement of health intervention impact on patient outcomes 158 
x Enhanced evidence base to inform policy 159 
Central to our success has been clinical engagement and designated, resourced, 160 
clinical leadership as a component of the program. This leadership has ensured that 161 
IIP aligned with clinical priorities and had a clear translational pathway to impact. 162 
Evidence generation from the exemplar studies is already shaping clinical practice 163 
(table 2)  0RYLQJ IRUZDUG FOLQLFLDQV¶ H[SHFWDWLRQV of IIP intelligence are twofold: 164 
incorporation into clinical decision tools available at the point of care to inform 165 
management of individual patient episodes, and timely tailored information resources, 166 
well visualised and clinically meaningful, to drive quality improvement.   167 
Future expansion of the range of datasets available through the IIP must address the 168 
current absence of both national patient level hospital prescribing data and laboratory 169 
data, beyond microbiology.  Both these gaps are recognised in our eHealth and 170 
informatics strategies for Scotland.13,14 A plan for rollout of Hospital Electronic 171 
Prescribing has been secured and the challenge of laboratory datasets is 172 
acknowledged as a priority for action. More collegiate working across NHS, academia 173 
and industry should be part of future solutions to enable more rapid innovation in data 174 
collation and analytics to improve health outcomes. Such an approach will also enable 175 
efficient utilisation of expanding data streams being generated through technology 176 
advancements, including next generation sequencing, diagnostics and behavioural 177 
risk factors.  178 
Encouragingly, we are not alone in the effort to build better intelligence and utilise 179 
routine data and record linkage to improve infectious disease surveillance.2,15,20    Like 180 
others we have found generation and use of indicators (AMR, antimicrobial use) at a 181 
population/geographical level, accessible to all stakeholders, is a strong foundation to 182 
identify an agenda for patient level analysis and a move towards point-of-care clinical 183 
decision support tools.  2XU ³EXLOGDQG WHVWSKDVH´ KDV LGHQWLILHGD QXPEHU RI key 184 
enablers, potentially transferable to other health care systems: government/policy 185 
support; unique patient identifier; strong clinical engagement and leadership; 186 
collaborative academic research DQG WHFKQRORJLFDO ³NQRZ KRZ´ with proportionate 187 
information governance.  We are part way along our IIP journey and have begun to 188 
increase our responsiveness to address important clinical questions that could be 189 
answered through a data linkage approach.  We hope our shared experience will 190 
inform and encourage others to embark upon this journey and catalyse opportunities 191 
for global collaboration.   192 
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Table 1: Datasets in NHS Scotland Infection Intelligence Platform  
Note:  NSS monitor data submissions in terms of completeness and quality through the Data Monitoring and Support Service and advise data users of any 
quality/completeness issues impacting on the use of data 
Name Description Update Frequency Earliest data Total number 
of records 
Prescribing Information 
System (PIS) 
Individual patient level data relating to community prescriptions written and 
dispensed within Scotland. 
 
Monthly 2009 ~1.2 billion 
Hospital Medicines 
Utilisation Database (HMUD) 
Non-patient level data sourced from hospital pharmacy stock control 
systems in Scotland containing information on aggregate issues of 
medicines to clinical areas.  
 
Monthly 2009 ~91 million 
Acute Scottish Morbidity 
Record (SMR01) data 
Individual patient level acute inpatient and day case activity data. 
 
Monthly 1997 ~91 million 
Mental health (SMR04) data Individual patient level mental health hospital activity data. 
 
Monthly 1997 ~1 million 
Maternity (SMR02)  data Individual patient level maternity units/hospital discharge data. 
 
Monthly 1981 ~4.5 million 
Deaths (SMR99) data Individual patient level death registrations data from the National Records 
of Scotland 
 
Monthly 1980 ~2.1 million 
Scottish Surgical Site 
Infection Reporting System 
(SSIRS) 
Individual patient level surgical site infection data. Caesarean section and 
hip arthroplasty are the two mandatory procedures required for SSI 
surveillance. 
 
Quarterly 2002 242,000 
Electronic Communication of 
Surveillance in Scotland 
(ECOSS) 
Individual patient level data on key (e.g. bacteraemia) positive 
microbiology laboratory specimen results and a subset of antimicrobial 
susceptibility/resistance data sourced from diagnostic microbiology 
laboratories within NHS Boards and national reference laboratories. 
Monthly 2007 ~29 million 
Table 2- Examples of key IIP studies (more information available at http://www.isdscotland.org/Health-Topics/Health-and-Social-
Community-Care/Infection-Intelligence-Platform/Study-Outputs) 
Study  Topic Rationale  Key Results Impact on clinical practice 
Measuring potential 
unintended consequences of 
reducing community 
antimicrobial prescribing16 
Safely reducing antimicrobial use is a 
priority to minimise development of 
AMR but clinicians are concerned that 
initiatives to reduce antimicrobial use 
could result in patients with serious 
infections not receiving treatment. 
The proportion of the Scottish population overall 
exposed to at least one antimicrobial in primary 
care, any time within the year, decreased by 1.6% 
from 32.2% in 2011 to 30.6% in 2014. Whereas 
antimicrobial use in the 30 days prior to admission 
for study patients increased by 1.9% over the 
study period, from 62.8% to 64.7%. 
 
These findings have been disseminated thorough 
national and local networks (SAPG, NHS Boards, IIP 
newsletter) to reassure clinicians that reductions in 
antimicrobial prescribing can be achieved without 
adversely impacting on patients who do require 
antimicrobials for respiratory infections.  
 
This analysis will be repeated on a regular basis to 
continue to reassure clinicians or allow early 
identification of any emerging unintended harm. 
Risk factors for antimicrobial 
resistance in community urine 
isolates17 
 
 
Urinary tract infections (UTI) are 
commonly encountered in primary 
care. Treatment is usually empiric but 
there are concerns about increasing 
resistance to these treatments in 
pathogens causing UTI. 
Analysis of 40984 community urine isolates 2012-
2015 showed older age, increasing co-morbidity, 
care home residence and antimicrobial use were 
associated with resistance and multi-drug 
resistance. Cumulative antimicrobial exposure in 
the six months preceding the isolate had a dose-
UHVSRQVHHIIHFW7KRVHSUHVFULEHGGHILQHG
daily doses (DDD) of antimicrobial were 5.53 
(95%CI 4.98-6.14) times more likely to have a 
multi-resistant pathogen. 
These data have been disseminated through national 
and local networks.  The output is now being used to 
design and test a clinical decision support tool which 
will enable clinicians to identify patients, at the point of 
prescribing, who are at higher risk of resistance in 
pathogens causing suspected UTI and thereby optimise 
initial antimicrobial treatment. 
 
 
Changes in HAI outcome over  
time18 
 
 
Surveillance of Clostridium difficile 
infection (CDI) in Scotland monitors 
trends in the number of new cases; 
however, there is no mortality  
information. This study examined 
mortality trends of CDI and 
established risk factors associated 
with death 
There was a decrease in all-cause mortality within 
30 days of diagnosis of CDI between 2009 and 
2013 with a year on year decrease in case-fatality.  
Older patients, those with a greater number of 
illnesses, and certain specific conditions such as 
lung, liver and malignancy were also associated 
with increased mortality. 
Further work focused on identifying those factors 
associated with increased survival will support quality 
improvement initiatives to enhance the clinical care of 
patients with CDI and assure better clinical outcomes. 
 
 
 
Association between 
antimicrobial exposure and 
HAI risk19 
 
 
The contribution of any antimicrobial, 
but particularly broad spectrum 
antimicrobials such as 
cephalosporins, fluoroquinolones, co-
amoxiclav and clindamycin is known 
to be associated with a higher risk of 
CDI but the temporal and cumulative 
association between community use 
of antimicrobials and community 
acquired CDI was not well described. 
Exposure to any antimicrobial but especially high 
risk broad spectrum antimicrobials in the previous 
six months increased the odds of CA-CDI.  
,QGLYLGXDOVZLWK DDD of high risk antimicrobial 
had an odds ratio of 17.9 (95% CI 7.6-42.2) 
compared to no antimicrobials. 
 
The elevated risk following high risk antimicrobials  
was still present 4-6 months after treatment 
(OR=2.6 (1.7-3.9) 
These findings have been disseminated thorough 
national and local networks, presented internationally 
and now published.  These data are now being used to 
generate risk models to create a decision support tool, 
ready for testing in primary care in 2018.   The outcome 
will be better assessment of the benefit and risk of 
treatment with any specific antimicrobials.  
 
 
 
